NASDAQ:GH Guardant Health (GH) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free GH Stock Alerts $24.73 +0.73 (+3.04%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$24.47▼$25.8550-Day Range$16.07▼$24.7352-Week Range$15.81▼$41.06Volume4.00 million shsAverage Volume1.93 million shsMarket Capitalization$3.03 billionP/E RatioN/ADividend YieldN/APrice Target$35.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Guardant Health alerts: Email Address Guardant Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside44.7% Upside$35.78 Price TargetShort InterestBearish8.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.51Upright™ Environmental ScoreNews Sentiment0.66Based on 13 Articles This WeekInsider TradingAcquiring Shares$38,972 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.49) to ($3.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector204th out of 2,771 stocksMedical Laboratories Industry10th out of 57 stocks 4.4 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGuardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Guardant Health's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.30% of the outstanding shares of Guardant Health have been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Guardant Health has recently increased by 6.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 71.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.51. Previous Next 2.6 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Guardant Health this week, compared to 4 articles on an average week.Search Interest28 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have bought 1,945.77% more of their company's stock than they have sold. Specifically, they have bought $38,972.00 in company stock and sold $1,905.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Guardant Health's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($3.49) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 18.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Guardant Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden FINISHED On June 13th?Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence. About Guardant Health Stock (NASDAQ:GH)Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Read More GH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GH Stock News HeadlinesMay 14 at 10:16 PM | markets.businessinsider.comBuy Rating Affirmed for Guardant Health Amid Strong Q1 Performance and Positive Revenue OutlookMay 13 at 8:39 PM | benzinga.comMarket Whales and Their Recent Bets on Guardant Health OptionsMay 13 at 3:39 PM | markets.businessinsider.comGuardant Health Receives ‘Buy’ Rating on Strong Q1 Performance and Positive Financial OutlookMay 13 at 3:39 PM | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Guardant Health (GH), Argenx Se (ARGX) and Annexon Biosciences (ANNX)May 13 at 10:38 AM | finance.yahoo.comGuardant Health, Inc. (NASDAQ:GH) Q1 2024 Earnings Call TranscriptMay 12 at 3:29 AM | americanbankingnews.comGuardant Health (NASDAQ:GH) Shares Gap Up to $19.44May 11 at 12:29 PM | finance.yahoo.comGuardant Health First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 11 at 12:29 PM | finance.yahoo.comGuardant Health, Inc. (NASDAQ:GH) Shares Could Be 44% Below Their Intrinsic Value EstimateMay 10, 2024 | benzinga.comGuardant Health Options Trading: A Deep Dive into Market SentimentMay 9, 2024 | businesswire.comGuardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceMay 7, 2024 | businesswire.comGuardant Health to Participate in Upcoming Investor ConferencesMay 7, 2024 | finance.yahoo.comGuardant Health Surpasses 500 Peer-Reviewed Publications MilestoneMay 5, 2024 | americanbankingnews.comGuardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 2, 2024 | wsj.comGuardant Health Inc.May 1, 2024 | msn.comNew World Bank Report Calls for Strengthening Resilience of Ghana's Health System in Response to Climate Change [press release]April 30, 2024 | msn.comGH Spoilers Weekly Preview Video: Valentin and Brennan Plan to Kill Two Birds with One StoneApril 30, 2024 | msn.com‘Remain steadfast towards achieving Universal Health Care’ – GhNCDA Coordinator to professionalsApril 26, 2024 | bizjournals.comCompany developing early cancer-detection tests to cut 20% of workforceApril 24, 2024 | stockhouse.comFDA Advisory Panel Review of Guardant Health's Shield(TM) Blood Test to Screen for Colorectal Cancer to Be Held on May 23April 22, 2024 | finance.yahoo.comFDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23April 22, 2024 | businesswire.comFDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23April 18, 2024 | businesswire.comGuardant Health to Report First Quarter 2024 Financial Results on May 9, 2024April 17, 2024 | msn.comMass. General Hospital granted unanimous approval to add dozens of inpatient bedsApril 17, 2024 | msn.comRomance Is In The Air On General HospitalApril 17, 2024 | msn.comGeneral Hospital Spoilers: Will Cyrus Decide Sonny's Prison Fate?See More Headlines Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,779Year FoundedN/APrice Target and Rating Average Stock Price Target$35.78 High Stock Price Target$50.00 Low Stock Price Target$27.00 Potential Upside/Downside+40.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-479,450,000.00 Net Margins-76.34% Pretax Margin-76.20% Return on Equity-246.47% Return on Assets-25.86% Debt Debt-to-Equity Ratio16.70 Current Ratio5.95 Quick Ratio5.66 Sales & Book Value Annual Sales$563.95 million Price / Sales5.54 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book19.06Miscellaneous Outstanding Shares122,370,000Free Float114,782,000Market Cap$3.13 billion OptionableNot Optionable Beta0.92 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Helmy Eltoukhy Ph.D. (Age 44)Co-Founder, Co-CEO & Chairman Comp: $11.63kDr. AmirAli Talasaz Ph.D. (Age 44)Co-CEO & Director Comp: $11.18kMr. Michael Bell (Age 55)Chief Financial Officer Comp: $630.99kMr. John G. Saia (Age 51)Chief Legal Officer & Corporate Secretary Comp: $627.18kDr. Craig Eagle M.D. (Age 57)Chief Medical Officer Comp: $649.13kMr. Christopher Freeman (Age 50)Chief Commercial Officer Comp: $630.39kMs. Darya ChudovaChief Technology OfficerMr. Kumud Kalia (Age 58)Chief Information Officer Ms. Jennifer HigginsVice President of Public AffairsMs. Terilyn Juarez Monroe (Age 57)Chief People Officer More ExecutivesKey CompetitorsVeracyteNASDAQ:VCYTFortreaNASDAQ:FTREViridian TherapeuticsNASDAQ:VRDNRadNetNASDAQ:RDNTCastle BiosciencesNASDAQ:CSTLView All CompetitorsInsiders & InstitutionsAmerican International Group Inc.Sold 478 shares on 5/14/2024Ownership: 0.045%EntryPoint Capital LLCBought 3,632 shares on 5/14/2024Ownership: 0.003%Edgestream Partners L.P.Bought 37,085 shares on 5/11/2024Ownership: 0.039%Vanguard Group Inc.Bought 305,372 shares on 5/10/2024Ownership: 9.396%Mitsubishi UFJ Trust & Banking CorpBought 402,310 shares on 5/10/2024Ownership: 0.331%View All Insider TransactionsView All Institutional Transactions GH Stock Analysis - Frequently Asked Questions Should I buy or sell Guardant Health stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares. View GH analyst ratings or view top-rated stocks. What is Guardant Health's stock price target for 2024? 12 equities research analysts have issued 1 year price targets for Guardant Health's stock. Their GH share price targets range from $27.00 to $50.00. On average, they expect the company's stock price to reach $35.78 in the next year. This suggests a possible upside of 44.7% from the stock's current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts. How have GH shares performed in 2024? Guardant Health's stock was trading at $27.05 at the beginning of the year. Since then, GH shares have decreased by 8.6% and is now trading at $24.73. View the best growth stocks for 2024 here. When is Guardant Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GH earnings forecast. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by $0.65. The company had revenue of $155.05 million for the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative net margin of 76.34% and a negative trailing twelve-month return on equity of 246.47%. What ETFs hold Guardant Health's stock? ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include Tema Oncology ETF (CANC), SPDR S&P Health Care Services ETF (XHS), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and ARK Genomic Revolution ETF (ARKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Guardant Health issued on next quarter's earnings? Guardant Health issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $675.0 million-$685.0 million, compared to the consensus revenue estimate of $664.0 million. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO). When did Guardant Health IPO? Guardant Health (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. Who are Guardant Health's major shareholders? Guardant Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.40%), Baillie Gifford & Co. (5.12%), Jennison Associates LLC (0.40%), Mitsubishi UFJ Trust & Banking Corp (0.33%), Sumitomo Mitsui Trust Holdings Inc. (0.26%) and Principal Financial Group Inc. (0.19%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Meghan V Joyce, Stanley J Meresman and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GH) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the MarketsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.